Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Rizatriptan
Overview
What is Rizatriptan?
Rizatriptan benzoate tablets contain rizatriptan benzoate, a selective 5-hydroxytryptamine (5-HT) receptor agonist.
Rizatriptan benzoate is described chemically as: -dimethyl-5-(1-1,2,4-triazol-1-ylmethyl)-1-indole-3-ethanamine monobenzoate and its structural formula is:
Its molecular formula is CHN•CHO, representing a molecular weight of the free base of 269.4. Rizatriptan benzoate, USP is a white to off-white, crystalline solid that is soluble in water at about 42 mg per mL (expressed as free base) at 25°C.
Rizatriptan benzoate tablets are available for oral administration in strengths of 5 mg and 10 mg (corresponding to 7.265 mg or 14.53 mg of the benzoate salt, respectively). Each compressed tablet contains the following inactive ingredients:
lactose monohydrate, microcrystalline cellulose, pregelatinized maize starch, ferric oxide (red), and magnesium stearate.
What does Rizatriptan look like?
What are the available doses of Rizatriptan?
• Rizatriptan Benzoate Tablets: 5 mg and 10 mg
What should I talk to my health care provider before I take Rizatriptan?
• Pregnancy: Based on animal data, may cause fetal harm
How should I use Rizatriptan?
R
Information related to usage of rizatriptan benzoate in pediatric patients (6 to 17 years old) is approved for Merck & Co., Inc.’s Rizatriptan Benzoate Tablets. However, due to Merck & Co., Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric patient (6 to 17 years old) usage information.
[see Contraindications ].
The recommended starting dose of rizatriptan benzoate tablets is either 5 mg or 10 mg for the acute treatment of migraines in adults. The 10 mg dose may provide a greater effect than the 5 mg dose, but may have a greater risk of adverse reactions : Although the effectiveness of a second dose or subsequent doses has not been established in placebo-controlled trials, if the migraine headache returns, a second dose may be administered 2 hours after the first dose. The maximum daily dose should not exceed 30 mg in any 24-hour period. The safety of treating, on average, more than four headaches in a 30-day period has not been established.
What interacts with Rizatriptan?
Sorry No Records found
What are the warnings of Rizatriptan?
Sorry No Records found
What are the precautions of Rizatriptan?
Sorry No Records found
What are the side effects of Rizatriptan?
Sorry No records found
What should I look out for while using Rizatriptan?
Rizatriptan benzoate tablets are contraindicated in patients with:• Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), or other significant underlying cardiovascular disease • Coronary artery vasospasm including Prinzmetal's angina • History of stroke or transient ischemic attack (TIA) • Peripheral vascular disease (PVD) • Ischemic bowel disease • Uncontrolled hypertension • Recent use (i.e., within 24 hours) of another 5-HT1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) • Hemiplegic or basilar migraine. • Concurrent administration or recent discontinuation (i.e., within 2 weeks) of a MAO-A inhibitor • Hypersensitivity to rizatriptan benzoate tablets (angioedema and anaphylaxis seen)
What might happen if I take too much Rizatriptan?
No overdoses of rizatriptan benzoate were reported during clinical trials in adults.
Some adult patients who received 40 mg of rizatriptan benzoate either a single dose or as two doses with a 2-hour interdose interval had dizziness and somnolence.
In a clinical pharmacology study in which 12 adult subjects received rizatriptan benzoate, at total cumulative doses of 80 mg (given within 4 hours), two of the subjects experienced syncope, dizziness, bradycardia including third degree AV block, vomiting, and/or incontinence.
In addition, based on the pharmacology of rizatriptan benzoate, hypertension or myocardial ischemia could occur after overdosage. Gastrointestinal decontamination, (i.e., gastric lavage followed by activated charcoal) should be considered in patients suspected of an overdose with rizatriptan benzoate. Clinical and electrocardiographic monitoring should be continued for at least 12 hours, even if clinical symptoms are not observed.
The effects of hemo- or peritoneal dialysis on serum concentrations of rizatriptan are unknown.
How should I store and handle Rizatriptan?
Store protected from light in the aluminum pouch at controlled room temperature (20° to 25°C [68° to 77°F]); excursions permitted to 15°to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Store at controlled room temperature (20° to 25°C [68° to 77°F]); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Store protected from light in the aluminum pouch at controlled room temperature (20° to 25°C [68° to 77°F]); excursions permitted to 15°to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Store at controlled room temperature (20° to 25°C [68° to 77°F]); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Rizatriptan Benzoate Tablets are available in strengths of 5 mg and 10 mg containing 7.265 mg or 14.53 mg of rizatriptan benzoate, USP equivalent to 5 mg or 10 mg of rizatriptan, respectively.The 5 mg tablets are pale pink, capsule-shaped, compressed tablets debossedwith 'CL 33' on one side and plain on the other. They are available as follows:NDC 33342-087-12 carton of 100 tabletsNDC 33342-087-07 container of 30 tabletsNDC 33342-087-46 container of 200 tabletsNDC 33342-087-50 carton of 12 tabletsNDC 33342-087-72 carton of 18 tablets The 10 mg tablets are pale pink, capsule-shaped, compressed tablets debossed"CL 34" on one side and plain on the other. They are available as follows:NDC 33342-088-12, carton of 100 tablets.NDC 33342-088-07 container of 30 tabletsNDC 33342-088-46 container of 200 tabletsNDC 33342-088-50 carton of 12 tabletsNDC 33342-088-72 carton of 18 tablets Rizatriptan Benzoate Tablets are available in strengths of 5 mg and 10 mg containing 7.265 mg or 14.53 mg of rizatriptan benzoate, USP equivalent to 5 mg or 10 mg of rizatriptan, respectively.The 5 mg tablets are pale pink, capsule-shaped, compressed tablets debossedwith 'CL 33' on one side and plain on the other. They are available as follows:NDC 33342-087-12 carton of 100 tabletsNDC 33342-087-07 container of 30 tabletsNDC 33342-087-46 container of 200 tabletsNDC 33342-087-50 carton of 12 tabletsNDC 33342-087-72 carton of 18 tablets The 10 mg tablets are pale pink, capsule-shaped, compressed tablets debossed"CL 34" on one side and plain on the other. They are available as follows:NDC 33342-088-12, carton of 100 tablets.NDC 33342-088-07 container of 30 tabletsNDC 33342-088-46 container of 200 tabletsNDC 33342-088-50 carton of 12 tabletsNDC 33342-088-72 carton of 18 tablets Rizatriptan Benzoate Tablets are available in strengths of 5 mg and 10 mg containing 7.265 mg or 14.53 mg of rizatriptan benzoate, USP equivalent to 5 mg or 10 mg of rizatriptan, respectively.The 5 mg tablets are pale pink, capsule-shaped, compressed tablets debossedwith 'CL 33' on one side and plain on the other. They are available as follows:NDC 33342-087-12 carton of 100 tabletsNDC 33342-087-07 container of 30 tabletsNDC 33342-087-46 container of 200 tabletsNDC 33342-087-50 carton of 12 tabletsNDC 33342-087-72 carton of 18 tablets The 10 mg tablets are pale pink, capsule-shaped, compressed tablets debossed"CL 34" on one side and plain on the other. They are available as follows:NDC 33342-088-12, carton of 100 tablets.NDC 33342-088-07 container of 30 tabletsNDC 33342-088-46 container of 200 tabletsNDC 33342-088-50 carton of 12 tabletsNDC 33342-088-72 carton of 18 tablets Rizatriptan Benzoate Tablets are available in strengths of 5 mg and 10 mg containing 7.265 mg or 14.53 mg of rizatriptan benzoate, USP equivalent to 5 mg or 10 mg of rizatriptan, respectively.The 5 mg tablets are pale pink, capsule-shaped, compressed tablets debossedwith 'CL 33' on one side and plain on the other. They are available as follows:NDC 33342-087-12 carton of 100 tabletsNDC 33342-087-07 container of 30 tabletsNDC 33342-087-46 container of 200 tabletsNDC 33342-087-50 carton of 12 tabletsNDC 33342-087-72 carton of 18 tablets The 10 mg tablets are pale pink, capsule-shaped, compressed tablets debossed"CL 34" on one side and plain on the other. They are available as follows:NDC 33342-088-12, carton of 100 tablets.NDC 33342-088-07 container of 30 tabletsNDC 33342-088-46 container of 200 tabletsNDC 33342-088-50 carton of 12 tabletsNDC 33342-088-72 carton of 18 tablets Rizatriptan Benzoate Tablets are available in strengths of 5 mg and 10 mg containing 7.265 mg or 14.53 mg of rizatriptan benzoate, USP equivalent to 5 mg or 10 mg of rizatriptan, respectively.The 5 mg tablets are pale pink, capsule-shaped, compressed tablets debossedwith 'CL 33' on one side and plain on the other. They are available as follows:NDC 33342-087-12 carton of 100 tabletsNDC 33342-087-07 container of 30 tabletsNDC 33342-087-46 container of 200 tabletsNDC 33342-087-50 carton of 12 tabletsNDC 33342-087-72 carton of 18 tablets The 10 mg tablets are pale pink, capsule-shaped, compressed tablets debossed"CL 34" on one side and plain on the other. They are available as follows:NDC 33342-088-12, carton of 100 tablets.NDC 33342-088-07 container of 30 tabletsNDC 33342-088-46 container of 200 tabletsNDC 33342-088-50 carton of 12 tabletsNDC 33342-088-72 carton of 18 tablets
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Rizatriptan binds with high affinity to human cloned 5-HT receptors. Rizatriptan presumably exerts its therapeutic effects in the treatment of migraine headache by binding to 5-HT receptors located on intracranial blood vessels and sensory nerves of the trigeminal system.
Non-Clinical Toxicology
Rizatriptan benzoate tablets are contraindicated in patients with:• Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), or other significant underlying cardiovascular disease • Coronary artery vasospasm including Prinzmetal's angina • History of stroke or transient ischemic attack (TIA) • Peripheral vascular disease (PVD) • Ischemic bowel disease • Uncontrolled hypertension • Recent use (i.e., within 24 hours) of another 5-HT1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) • Hemiplegic or basilar migraine. • Concurrent administration or recent discontinuation (i.e., within 2 weeks) of a MAO-A inhibitor • Hypersensitivity to rizatriptan benzoate tablets (angioedema and anaphylaxis seen)Thiazides may add to or potentiate the action of other antihypertensive drugs.
The thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. Thiazides have also been shown to increase responsiveness to tubocurarine.
Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity. Refer to the package insert on lithium before use of such concomitant therapy.
Acute renal failure has been reported in a few patients receiving indomethacin and formulations containing triamterene and hydrochlorothiazide. Caution is therefore advised when administering nonsteroidal anti-inflammatory agents with triamterene and hydrochlorothiazide.
Potassium-sparing agents should be used very cautiously, if at all, in conjunction with angiotensin-converting enzyme (ACE) inhibitors due to a greatly increased risk of hyperkalemia. Serum potassium should be monitored frequently.
Rizatriptan benzoate should not be given to patients with ischemic or vasospastic coronary artery disease. There have been rare reports of serious cardiac adverse reactions, including acute myocardial infarction, occurring within a few hours following administration of rizatriptan benzoate. Some of these reactions occurred in patients without known coronary artery disease (CAD). 5-HT agonists including rizatriptan benzoate may cause coronary artery vasospasm (Prinzmetal's Angina), even in patients without a history of CAD.
Triptan-naïve patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) should have a cardiovascular evaluation prior to receiving rizatriptan benzoate. If there is evidence of CAD or coronary artery vasospasm, rizatriptan benzoate should not be administered For patients who have a negative cardiovascular evaluation, consideration should be given to administration of the first rizatriptan benzoate dose in a medically-supervised setting and performing an electrocardiogram (ECG) immediately following rizatriptan benzoate administration. Periodic cardiovascular evaluation should be considered in intermittent long-term users of rizatriptan benzoate who have cardiovascular risk factors.
The following adverse reactions are discussed in more detail in other sections of the labeling:• Myocardial Ischemia, Myocardial Infarction, and Prinzmetal's Angina • Arrhythmias • Chest and or Throat, Neck and/or Jaw Pain/Tightness/Pressure • Cerebrovascular Events • Other Vasospasm Reactions • Medication Overuse Headache • Serotonin Syndrome • Increase in Blood Pressure
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
516Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).